Colgate-Palmolive (NYSE: CL) director adds 301 shares via fee deferral
Rhea-AI Filing Summary
Colgate-Palmolive Company director reports deferred stock award
A director of Colgate-Palmolive Company reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share. According to the footnote, this reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than a market purchase for cash.
Following this transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust. The filing confirms the individual’s status as a director and that the report is filed for one reporting person.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did Colgate-Palmolive (CL) report in this Form 4?
A Colgate-Palmolive director reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share.
How were the new Colgate-Palmolive (CL) shares obtained by the director?
The 301 shares were credited as a portion of the director’s annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than through an open-market purchase.
How many Colgate-Palmolive (CL) shares does the director own after this transaction?
After the reported transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust, as disclosed in the filing.
What is the relationship of the reporting person to Colgate-Palmolive (CL)?
The reporting person is identified as a Director of Colgate-Palmolive Company and is not listed as a 10% owner or officer in this report.
Is this Colgate-Palmolive (CL) Form 4 filed for more than one reporting person?
No. The filing indicates that the Form is filed by one reporting person, not by a group or multiple insiders.
What address is associated with the reporting person in the Colgate-Palmolive (CL) filing?
The address listed is C/O Colgate-Palmolive Company, 300 Park Avenue, which is associated with the reporting director for this Form 4 filing.